JLE

Médecine de la Reproduction

MENU

Indication et pratique de la préservation médicale non oncologique de la fertilité Volume 20, numéro 1, Janvier-Février-Mars 2018

  • [1] Garcia-Velasco J.A., Domingo J., Cobo A., Martinez M., Carmona L., Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99:1994-1999.
  • [2] Ott J., Nouri K., Stogbauer L. Ovarian tissue cryopreservation for non-malignant indications. Arch Gynecol Obstet. 2010;281:735-739.
  • [3] Imbert R., Moffa F., Tsepelidis S. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod. 2014;29:1931-1940.
  • [4] Gellert S.E., Pors S.E., Kristensen S.G., Bay-Bjorn A.M., Ernst E., Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35:561-570.
  • [5] Martinez F. Update on fertility preservation from the Barcelona international society for fertility preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Hum Reprod. 2017;32:1802-1811.
  • [6] Sanders J.E., Woolfrey A.E., Carpenter P.A. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood. 2011;118:1421-1428.
  • [7] Sanders J.E., Hawley J., Levy W. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045-3052.
  • [8] Loren A.W., Chow E., Jacobsohn D.A. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for international blood and marrow transplant research (CIBMTR). Biol Blood Marrow Transplant. 2011;17:157-166.
  • [9] Vatanen A., Wilhelmsson M., Borgstrom B. Ovarian function after allogeneic hematopoietic stem cell transplantation in childhood and adolescence. Eur J Endocrinol. 2014;170:211-218.
  • [10] Kassim A.A., Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017;10:259-266.
  • [11] Slatter M.A., Boztug H., Potschger U. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone marrow transplantation. 2015;50:1536-1541.
  • [12] Panasiuk A., Nussey S., Veys P. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan. Br J Haematol. 2015;170:719-726.
  • [13] Singer S.T., Sweeters N., Vega O., Higa A., Vichinsky E., Cedars M. Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann N Y Acad Sci. 2010;1202:226-230.
  • [14] Reubinoff B.E., Har-El R., Kitrossky N. Increased levels of redox-active iron in follicular fluid: a possible cause of free radical-mediated infertility in beta-thalassemia major. Am J Obstet Gynecol. 1996;174:914-918.
  • [15] Singer S.T., Vichinsky E.P., Gildengorin G., van Disseldorp J., Rosen M., Cedars M.I. Reproductive capacity in iron overloaded women with thalassemia major. Blood. 2011;118:2878-2881.
  • [16] Elchuri S.V., Williamson R.S., Clark Brown R. The effects of hydroxyurea and bone marrow transplant on Anti-Mullerian hormone (AMH) levels in females with sickle cell anemia. Blood Cells Mol Dis. 2015;55:56-61.
  • [17] Demeestere I., Simon P., Dedeken L. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015;30:2107-2109.
  • [18] Hijmans C.T., Grootenhuis M.A., Oosterlaan J. Behavioral and emotional problems in children with sickle cell disease and healthy siblings: multiple informants, multiple measures. Pediatr Blood Cancer. 2009;53:1277-1283.
  • [19] Lavery S.A., Islam R., Hunt J., Carby A., Anderson R.A. The medical and ethical challenges of fertility preservation in teenage girls: a case series of sickle cell anaemia patients prior to bone marrow transplant. Hum Reprod. 2016;31:1501-1507.
  • [20] Balduzzi A., Dalle J.H., Jahnukainen K. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the pediatric diseases working party of the EBMT and the international BFM study group. Bone Marrow Transplant. 2017;52:1406-1415.
  • [21] Reichman D.E., Davis O.K., Zaninovic N., Rosenwaks Z., Goldschlag D.E. Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome. Fertil Steril. 2012;98:1225-1228.
  • [22] Nahata L., Sivaraman V., Quinn G.P. Fertility counseling and preservation practices in youth with lupus and vasculitis undergoing gonadotoxic therapy. Fertil Steril. 2016;106:1470-1474.
  • [23] Boumpas D.T., Austin HA. 3rd, Vaughan E.M., Yarboro C.H., Klippel J.H., Balow J.E. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-369.
  • [24] Manger K., Wildt L., Kalden J.R., Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006;5:269-272.
  • [25] Henes J.C., Henes M., von Wolff M., Schmalzing M., Kotter I., Lawrenz B. Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol. 2012;30:S53-56.
  • [26] Goswami RP, Sircar G, Sit H, Ghosh A, Ghosh P. Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: a historical head-to-head comparative study. J Clin Rheumatol 2018 Mar 21. doi: 10.1097/RHU.0000000000000760. [Epub ahead of print]
  • [27] Mok C.C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:429-438.
  • [28] Andreoli L., Bertsias G.K., Agmon-Levin N. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476-485.
  • [29] Bellver J., Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803-1810.
  • [30] Courbiere B., Decanter C., Bringer-Deutsch S. Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. Hum Reprod. 2013;28:2381-2388.
  • [31] Sioulas V.D., Gracia C.R. Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: Is it safe? J Assist Reprod Genet. 2012;29:271-275.
  • [32] Elizur S.E., Chian R.C., Pineau C.A. Fertility preservation treatment for young women with auto-immune diseases facing treatment with gonadotoxic agents. Rheumatology. 2008;47:1506-1509.
  • [33] Henes M., Henes J.C., Neunhoeffer E. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus. 2012;21:953-958.
  • [34] Guzman-Soto I., Salinas E., Hernandez-Jasso I., Quintanar J.L. Leuprolide acetate, a GnRH agonist, improves experimental auto-immune encephalomyelitis: a possible therapy for multiple sclerosis. Neurochem Res. 2012;37:2190-2197.
  • [35] Lambertini M., Boni L., Michelotti A. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632-2640.
  • [36] Moore H.C., Unger J.M., Phillips K.A. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923-932.
  • [37] Marder W., McCune W.J., Wang L. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28:624-627.
  • [38] Blumenfeld Z., Shapiro D., Shteinberg M., Avivi I., Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9:401-405.
  • [39] Lawrenz B., Henes J., Henes M. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20:1193-1197.
  • [40] Tsigkou A., Marzotti S., Borges L. High serum inhibin concentration discriminates auto-immune oophoritis from other forms of primary ovarian insufficiency. J Clin Endocrinol Metab. 2008;93:1263-1269.
  • [41] Welt C.K. Autoimmune oophoritis in the adolescent. Ann N Y Acad Sci. 2008;1135:118-122.
  • [42] Dadoun Y., Azais H., Keller L., d’Orazio E., Collinet P., Decanter C. Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors. Gynecol Obstet Fertil Senol. 2017;45:359-365.
  • [43] Carrillo L., Seidman D.S., Cittadini E., Meirow D. The role of fertility preservation in patients with endometriosis. J Assist Reprod Genet. 2016;33:317-323.
  • [44] Kitajima M., Defrere S., Dolmans M.M. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011;96:685-691.
  • [45] Somigliana E., Vigano P., Filippi F. Fertility preservation in women with endometriosis: for all, for some, for none? Hum Reprod. 2015;30:1280-1286.
  • [46] Darai E., Fauvet R., Uzan C., Gouy S., Duvillard P., Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19:151-166.
  • [47] Mangili G., Somigliana E., Giorgione V. Fertility preservation in women with borderline ovarian tumours. Cancer Treat Rev. 2016;49:13-24.
  • [48] Masciangelo R., Bosisio C., Donnez J., Amorim C.A., Dolmans M.M. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Reprod. 2018;33:212-219.
  • [49] Gleicher N., Kushnir V.A., Barad D.H. Prospectively assessing risk for premature ovarian senescence in young females: a new paradigm. Reprod Biol Endocrinol. 2015;13:34.